Top 50 Health Care Startup Investors in China (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Qiming Venture Partners
VC Fund
|
98 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5M–$134M |
|
BioVenture
VC Fund
|
70 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3M–$73M |
|
HSG
VC Fund
|
55 | China, United States, Hong Kong | Series A, Series B, Series C | Health Care, Biotechnology, Software | $4.4M–$214M |
|
Med-Fine Capital
VC Fund
|
49 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $2.8M–$60M |
|
Lilly Asia Ventures
VC Fund
|
44 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$283M |
|
Frees Fund
VC Fund
|
42 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Health Care, Biotechnology | $425k–$35M |
|
Legend Capital
VC Fund
|
41 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.9M–$156M |
|
Highlight Capital
VC Fund
|
40 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $2.8M–$74M |
|
IDG Capital
VC Fund
|
39 | China, United States, India | Series A, Series B, Series C | Software, Internet, E-Commerce | $3M–$200M |
|
Matrix Partners China
VC Fund
|
38 | China, United States, Singapore | Series A, Series B, Seed | Health Care, Biotechnology, Software | $1.6M–$113M |
|
Puhua Capital
VC Fund
|
37 | China, United Kingdom, United States | Series A, Series B, Seed | Health Care, Medical, Manufacturing | $1.4M–$112M |
|
Kaitai Capital
VC Fund
|
34 | China, United States, Singapore | Series A, Seed, Series B | Biotechnology, Health Care, Pharmaceutical | $1.4M–$57M |
|
BioTrack Capital
VC Fund
|
33 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $14M–$168M |
|
Shenzhen Capital Group
VC Fund
|
32 | China, United States, Japan | Series A, Series B, Series C | Manufacturing, Health Care, Software | $1.5M–$156M |
|
Marathon Venture Partners
VC Fund
|
31 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.4M–$462M |
|
Cowin Capital
VC Fund
|
30 | China, Hong Kong, United States | Series A, Series B, Seed | Manufacturing, Health Care, Biotechnology | $1.4M–$50M |
|
Dalton Venture
VC Fund
|
30 | China, India, Canada | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $450k–$47M |
|
Shanghai Biomedical Industrial Equity Investment Fund
VC Fund
|
30 | China, United States, Hong Kong | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $8M–$142M |
|
Northern Light Venture Capital
VC Fund
|
29 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.3M–$100M |
|
Legend Star
VC Fund
|
28 | China, United States, France | Series A, Seed, Angel | Health Care, Medical, Robotics | $425k–$112M |
|
Sherpa Healthcare Partners
VC Fund
|
27 | China, United States, Kenya | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.8M–$156M |
|
CDH Investments
VC Fund
|
27 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Biotechnology, Health Care | $7.1M–$300M |
|
CD Capital
VC Fund
|
27 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
Lenovo Capital and Incubator Group (LCIG)
VC Fund
|
26 | China, Hong Kong, United States | Series A, Seed, Series B | Manufacturing, Artificial Intelligence, Software | $1.5M–$150M |
|
Prox Ventures
VC Fund
|
25 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $1.9M–$28M |
|
Cowin Venture
VC Fund
|
24 | China, United States, Hong Kong | Series A, Angel, Series B | Health Care, Medical, Biotechnology | $425k–$257M |
|
Jan Hammer
Angel
|
24 | China, United States, France | Series A, Series B, Seed | Health Care, Medical, Medical Device | $2.5M–$250M |
|
Longpan Investment
VC Fund
|
24 | China, United States, Cayman Islands | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $14M–$60M |
|
Oriza Holdings
VC Fund
|
23 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $1.7M–$200M |
|
Green Pine Capital Partners
VC Fund
|
23 | China, United States, Canada | Series A, Series B, Angel | Artificial Intelligence, Biotechnology, Health Care | $425k–$150M |
|
Share Capital
VC Fund
|
23 | China, United States, Colombia | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $142k–$57M |
|
Pan-Lin Capital
VC Fund
|
22 | China, United States, Canada | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $1.4k–$57M |
|
TF Capital
VC Fund
|
21 | China, United States | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$1.4B |
|
Oriza Seed Capital (Oriza Yuandian)
VC Fund
|
20 | China, United States, Singapore | Series A, Seed, Angel | Manufacturing, Health Care, Medical | $213k–$60M |
|
Addor Capital
VC Fund
|
20 | China, Hong Kong, Singapore | Series A, Series B, Seed | Manufacturing, Semiconductor, Electronics | $1.4k–$43M |
|
Shunwei Capital
VC Fund
|
20 | China, United States, India | Series A, Series B, Series C | Manufacturing, Software, Internet | $1.4M–$100M |
|
Taiyu Investment
VC Fund
|
20 | China | Seed, Series A, Angel | Medical, Health Care, Biotechnology | $4.1M–$37M |
|
Gaorong Capital
VC Fund
|
20 | China, United States, Hong Kong | Series A, Series B, Seed | Information Technology, Software, Artificial Intelligence | $2.8M–$120M |
|
Huagai Capital
VC Fund
|
20 | China, United States, Germany | Series A, Series B, Angel | Health Care, Biotechnology, Medical | $425k–$147M |
|
EFung Capital
VC Fund
|
20 | China, United States, India | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $1.4M–$87M |
|
Lotus Lake Ventures
VC Fund
|
20 | China, India | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $42k–$97M |
|
Sinopharm Capital
VC Fund
|
19 | China, United States, Canada | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $1.4M–$114M |
|
Volcanics Venture
VC Fund
|
19 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Artificial Intelligence, Biotechnology | $350k–$60M |
|
Tiantu Capital
VC Fund
|
18 | China, United States, Japan | Series A, Series B, Series C | Food and Beverage, E-Commerce, Health Care | $1.4M–$162M |
|
ZhenFund
VC Fund
|
18 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Software, E-Commerce | $425k–$28M |
|
Oriental Fortune Capital
VC Fund
|
18 | China, United States | Series A, Series B, Seed | Software, Manufacturing, Information Technology | $1.4M–$100M |
|
Plum Ventures
VC Fund
|
18 | China, United States, Hong Kong | Series A, Angel, Seed | E-Commerce, Manufacturing, Software | $425k–$16M |
|
Hillhouse Investment
VC Fund
|
18 | China, United States, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Software | $2.9M–$220M |
|
Sinovation Ventures
VC Fund
|
18 | China, United States, Singapore | Series A, Seed, Series B | Software, Artificial Intelligence, Internet | $1M–$110M |
|
CASH Capital
VC Fund
|
18 | China, United States | Series A, Series B, Series C | Health Care, Manufacturing, Biotechnology | $1.4M–$113M |
| Access all 4611 investors in China Health Care startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 803
- Round size: Series A $5M–$68M; Series B $9.4M–$100M; Series C $14M–$134M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $887M in 2023
Portfolio highlights
- Nice Tuan — Nice Tuan is an e-commerce platform that provides daily groceries and miscellaneous products.
- Twine Health — Fitbit Health Solutions' wellness and health solutions can help keep your population healthy and drive meaningful employee engagement. Learn more.
- WindMIL Therapeutics — WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients. The company leveraging its proprietary platform to develop a novel class of cell therapies called MILs (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow. WindMIL Therapeutics wasestablished in 2015 and is based in Baltimore, MD.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 168
- Round size: Seed $7.1M–$41M; Series A $3.8M–$47M; Series B $3M–$73M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Dami&Xiaomi — Rice and millet is China's leading platform services for children with autism spectrum, from 2014 Nian 9 Yue Jiang Ying Shuang (rice) founded the "rice and millet" micro-channel public number. It now provides integrated services such as rehabilitation services, integrated education support, parent training, online courses, andpopular science information.
- CART Medical — CART Medical Technologies, Ltd. is a high-tech company specializing in the development and application of new technologies for immune cell therapy. It has a 2,200 square meter GMP laboratory and research and development laboratory.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
We help founders build enduring companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 751
- Round size: Series A $4.4M–$100M; Series B $12M–$200M; Series C $26M–$214M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- MarqVision — Effortlessly discover and remove counterfeits to protect your sales and reputation.
- Midas — Midas is the first neobroker of Turkey, providing zero commission Turkish and American stocks.
- Yunzhou Zhiwei — Yunzhou Zhiwei is a high-tech startup focused on serving large-scale equipment maintenance industries such as aviation, aerospace, shipbuilding, and rail transit. It leverages smart maintenance concepts and advanced digital technologies to make complex equipment maintenance more efficient and lean. The company drives industrial transformationtoward intelligent maintenance, helping enterprises enhance growth, efficiency, and operational excellence.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 80
- Round size: Seed $8M–$60M; Series A $2.8M–$40M; Series B $11M–$60M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $69M in 2019
Portfolio highlights
- Med-Vision — Virtual reality (VR) medical care service provider based in Hangzhou.
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 217
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $29M–$283M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
- Tmunity Therapeutics — Tmunity Therapeutics is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), universal engineered T cell platforms, and Chimeric Antigen....
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 213
- Round size: Seed $1.4M–$14M; Angel $425k–$17M; Series A $1.4M–$35M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $130M in 2015
Portfolio highlights
- SoundAI — Sound Technology is a science and technology innovation company that specializes in acoustics frontier technology and artificial intelligence interaction. It is committed to lead the more interactive experience of artificial intelligence in the real environment and realize the human-computer interaction vision that "listen to you and know whatyou think".
- Methuselah — Methuselah is a research and development manufacturer of medical nutritional food.
- Jiajin Biotech — Jiajin Biotech is a pharmaceutical R&D service provider. It specializes in the development of antibody-small nucleic acid conjugates.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 410
- Round size: Series A $2.9M–$93M; Series B $12M–$115M; Series C $14M–$156M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Pony.ai — Pony.ai is a startup that builds full-stack autonomous driving solutions. It is a pioneer in autonomous mobility technologies and services across the US and China, spearheading public-facing Robotaxi pilots in both markets. Pony.ai is committed to creating a safe and sustainable mobility future by delivering autonomous mobility everywhere.Thecompany was founded by James Peng and Tiancheng Lou in 2016 and is headquartered in Fremont, California, United States.
- Sifli Technologies — Sifli Technologies focuses on the design and application development of embedded artificial intelligence IoT platforms.
- Biortus — Wuxi Biortus Biosciences is an innovation-driven contract research organization (CRO) committed to high-quality R&D services in support of drug discovery.To help our clients achieve their drug discovery goals, we have established five world-class research platforms. These are Recombinant Protein Production, Structural Biology (X-rayCrystallography and Cryo-EM), In Vitro Assays and Screening, Medicinal Chemistry, and Process Development. Through the years, our R&D team has developed a number of practical and innovative techniques of which some have already been granted patent.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 166
- Round size: Seed $10M–$73M; Series A $2.8M–$74M; Series B $7.6M–$70M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Approaching.AI — Approaching.AI is an AI Infra company focusing on the important large model application scenarios such as RAG.
- Xingneng Xuanguang — Xingneng Xuanguang is a fusion energy company that specializes in the development of advanced field reverse magnetic mirror fusion path technology.
- Blue Vector Intelligent — Blue Vector Intelligent is a company primarily engaged in software and information technology services, specializing in the development of intelligent software solutions, data-driven platforms, and digital transformation technologies.
IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Software, Internet, E-Commerce
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 752
- Round size: Series A $3M–$122M; Series B $8.3M–$141M; Series C $15M–$200M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Polymaker — Polymaker is a high quality 3D printing filament manufacturers. PLA, PETG, ABS, ASA, TPU, Nylon, PC, Carbon Fiber and more. Find the best filament for your application.
- Youxi Film Hotel — Youxi Film Hotel which is a hotel in China that combines the perfect combination of hotel and movie IP. It is also a movie hotel theme, combining film derivative industry, movie theme social space and film shooting. An integrated creative culture complex; dedicated to creating a Chinese-style movie and hotel cross-border experience hotel, breakingthrough the traditional overnight function of a traditional hotel, creating the ultimate movie experience for young people with a mindset.
- Liyang Semiconductor — Liyang Semiconductor is a power semiconductor chip developer, integrating design and development, chip manufacturing, packaging and testing
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 459
- Round size: Seed $1.6M–$32M; Series A $2.9M–$57M; Series B $10M–$113M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- TT Yuyin — Quwan provides services including instant voice messaging, social gaming, esports, and game distribution. It operates TT Voice, which started as a voice chat application designed for mobile gamers and was later developed into a social gaming platform. It focuses on developing personalized services for the Gen Z audience.
- Huangbaoche — Huangbaoche is a travel service providing tour packages and booking services. Huangbaoche has over 100,000 Chinese-speaking drivers and tour guides providing airport pick-up services, chartered car services, and guided tours in over 1,500 overseas travel destination cities in 80 countries.
- Jiajin Biotech — Jiajin Biotech is a pharmaceutical R&D service provider. It specializes in the development of antibody-small nucleic acid conjugates.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.
Show more...Investment focus
- Industry: Health Care, Medical, Manufacturing
- Stage:Series A, Series B, Seed
- Geography: China, United Kingdom, United States
Investor stats
- Total investments: 237
- Round size: Seed $1.4M–$29M; Series A $1.4M–$112M; Series B $2.8M–$103M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- DeepWay — DeepWay is a maker and developer of intelligent electric commercial vehicles.
- Nuoyun Drive —
- Ganzhicao Technology — Gancao Doctor is an internet-based Traditional Chinese Medicine (TCM) company that helps clinics modernize their digital management and optimize operations. By using AI-assisted features, it enhances doctors' diagnostic and treatment abilities, delivering valuable benefits to doctors, patients, and clinics.
KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 131
- Round size: Seed $2.4M–$20M; Series A $1.4M–$35M; Series B $4.3M–$57M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Aoquan —
- Nafi Pharmaceuticals — Nafi Pharmaceuticals develops novel medications for central nervous system illnesses.
- Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 92
- Round size: Seed $14M–$168M; Series A $14M–$45M; Series B $14M–$150M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Huihe Healthcare — Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China.
- LaNova Medicines — LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
- Zhiyue Space Intelligence — Zhiyue Space Intelligence specializes in robotic brain and brain systems.
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 487
- Round size: Series A $1.5M–$156M; Series B $14M–$142M; Series C $4.3M–$142M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
Marathon Venture Partners is an international VC fund that focuses on early and growth stage companies in healthcare and Fintech industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 63
- Round size: Seed $7M–$13M; Series A $1.4M–$16M; Series B $14M–$462M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Fungifuture — Fungifuture is a synthetic biomaterials company specializing in the research and development and production of fungal fiber materials.
- Ruize Health — Ruize Health is a commercial insurance company that focuses on health consumption and commercial insurance.
- Fuxin Technology Innovation — Fuxin Kechuang is a high-tech company that specializes in offering detailed information solutions for the medical and healthcare industries. The business offers creative software solutions and services to a range of healthcare organizations, actively supports the digital transformation of healthcare, and uplifts the medical sector. The company hasgained recognition and has become a partner of big and medium-sized medical institutions and healthcare institutions by relying on its technological research and development power, service capabilities, and ecosystem of medical and health software.
Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 306
- Round size: Seed $1.4M–$20M; Series A $4.3M–$41M; Series B $2.8M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- QYSEA — QYSEA FIFISH 4K underwater video camera is combined with the world's advanced techniques, supports 20-megapixel photos shooting in various conditions. QYSEA underwater ROV drone with great durability & design. QYSEA - professional underwater drone manufacturer!
- Bytetree — Bytetree is a technology company that focuses on providing the one-stop AI data services for data collection, cleaning, labeling, management, and storage for OEMs and autonomous driving solution providers, covering bicycle intelligence. , vehicle-road coordination, and smart cockpit three scenarios.
- Yinli Electric — Ningxia Yinli Electric Co., Ltd. is mainly engaged in the production and research and development of reactors and transformers. At present, the company's main products include: three-phase filter reactors, four-phase five-column reactors, water-cooled reactors, three-phase AC reactors, hollow core Reactors, isolation transformers andhigh-frequency transformers, etc.
Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: China, India, Canada
Investor stats
- Total investments: 139
- Round size: Seed $450k–$5M; Series A $2.8M–$17M; Series B $2.8M–$47M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Kongshanci — Kongshanci specializes in non-invasive brain-computer interfaces and neuromodulation.
- PowerMicro — PowerMicro focuses on the cutting-edge interdisciplinary field of “stem cells + engineered scaffolds,” specializing in the application of iPSC technology to advance regenerative medicine, tissue engineering, and innovative therapeutic solutions.
- Baiyao Technology — Baiyao Technology is a biopharmaceuticals company offering drug and treatment plan development utilizing AI simulation of life processes.
Shanghai Biomedical Industrial Equity focuses on areas that are in line with the development strategy of the biomedical industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 67
- Round size: Seed $8M–$50M; Series A $10M–$43M; Series B $14M–$142M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Beixcell — Beixcell develops off-the-shelf cell therapies for patients with many degenerative diseases through universal iPSCs-derived cell products.
- BioGeometry — BioGeo is an innovative digital startup that specializes in using generative AI in protein creation. BioGeo is dedicated to producing programmable proteins from scratch and utilizing them in synthetic biology and biomedicine by employing artificial intelligence-driven techniques to create links between protein sequence, structure, and function.
- Surgerii Technology — Beijing Surrey is a technology company founded by an industry elite active in China's medical equipment. Relying on the core technology of the new generation of flexible continuum robotic arm, running through the implementation paradigm of many types of clinical minimally invasive surgery, and harnessing the powerful system design andintegration capabilities, Beijing Shurui is committed to becoming the first independent independent research and development, production and sales in China.
Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 244
- Round size: Seed $1.3M–$100M; Series A $4.3M–$52M; Series B $11M–$62M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
- Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.Legend Star is the independent early-stage investment arm of LegendHoldings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.
Show more...Investment focus
- Industry: Health Care, Medical, Robotics
- Stage:Series A, Seed, Angel
- Geography: China, United States, France
Investor stats
- Total investments: 144
- Round size: Seed $1.4M–$19M; Angel $425k–$7.1M; Series A $1.4M–$112M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $109M in 2018
Portfolio highlights
- LifeLabs Design — LifeLabs patented warming & cooling technology allows for comfort across extreme temperatures. Explore our dedication to producing sustainable & eco-friendly fabrics.
- StarNuclear Fusion — StarNuclear Fusion is focused on the "high-temperature superconductivity + advanced quasi-isotropic propulsion (QI)" stellarator technology roadmap.
- ChipSense Technology — ChipSense Technology is a semiconductor focused on developing high-performance chips for AI computing infrastructure. The company provides chip solutions that enable perception and efficiency management in AI computing centers, helping optimize resource utilization, operational efficiency, and intelligent management of large-scale AI computingclusters.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Kenya
Investor stats
- Total investments: 100
- Round size: Series A $2.8M–$50M; Series B $15M–$100M; Series C $12M–$156M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Yosemite Clinic — Yosemite Clinic is a full-service clinic providing convenient walk-in medical services in a state-of-the-art environment in Central Pudong. They offer family medicine, internal medicine, surgery, orthopedics (sports medicine), dermatology, medical cosmetology, dentistry, gynecology, pediatrics, ophthalmology, anesthesiology, rehabilitationmedicine, medical imaging, laboratory, pharmacy and more. Their onsite facilities and equipment include CT, X-ray, Ultrasound, Laboratory and Operating Rooms. Their doctors come from China and across the world, enabling us to serve you in many languages including, English, Japanese, Malay, Mandarin Chinese and Cantonese.
- Archimedes Vascular — Archimedes Vascular operates as a medical device company, that treat patients with severe hypertension.
- Biortus — Wuxi Biortus Biosciences is an innovation-driven contract research organization (CRO) committed to high-quality R&D services in support of drug discovery.To help our clients achieve their drug discovery goals, we have established five world-class research platforms. These are Recombinant Protein Production, Structural Biology (X-rayCrystallography and Cryo-EM), In Vitro Assays and Screening, Medicinal Chemistry, and Process Development. Through the years, our R&D team has developed a number of practical and innovative techniques of which some have already been granted patent.
CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 285
- Round size: Series A $7.1M–$100M; Series B $14M–$142M; Series C $14M–$300M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- HitGen — HitGen is provides biological reagents and services to support drug discovery research.
- ZSPepLib — Zonsen PepLib Biotech Inc. Zonsen PepLib Biotech Inc. is a high-tech biopharmaceutical enterprise that is dedicated to advancing global innovation in the discovery of new peptide drugs. Founded in September 2017, PepLib is headquartered in Zhuzhou, China, with a subsidiary in New Jersey, USA.
- Eyegood Ophthalmic Hospital — Eyegood Ophthalmic Hospital is a ophthalmology hospital.
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 70
- Round size: Seed $1.4M–$15M; Series A $1.4M–$32M; Series B $7.1M–$34M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
- Pipi Bear —
- Senas Medical — Senas Medical focuses on innovative cardiac electrophysiology solutions.
Lenovo Capital and Incubator Group is an accelerator and venture capital firm.
Show more...Investment focus
- Industry: Manufacturing, Artificial Intelligence, Software
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 265
- Round size: Seed $1.5M–$42M; Series A $2.8M–$73M; Series B $5.5M–$150M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $500M in 2016
Portfolio highlights
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
- SenseTime Medical — SenseTime Medical promotes the development and implementation of its medical big model and provides smart health solutions.
- Shenzhen Urban Transport planning Center — Shenzhen Urban Transport planning Center provides traffic information engineering and technical services in China.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 79
- Round size: Seed $1.9M–$5.6M; Series A $2.8M–$28M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Founded in 2009, Cowin Venture is an angel and early-stage investor in TMT and Healthcare. We keep nurturing growth-stage companies graduated from their angel investment portfolio. Cowin’s business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing and Hong Kong.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Angel, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 100
- Round size: Angel $425k–$1.4M; Series A $1.4M–$25M; Series B $2.8M–$257M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- CytoChip —
- Amador Bioscience — At Amador we provide global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies.
- StringMotion Future — StringMotion Future focuses on the core technology research and development of tendon-inspired chord-driven robots, creating advanced robotic systems designed to deliver greater flexibility, precision, and efficiency for industrial and intelligent automation applications.
Jan Hammer is the partner at Index and the Board observer of Harmonic. Jan attended Oxford University.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States, France
Investor stats
- Total investments: 80
- Round size: Seed $2.5M–$113M; Series A $2.8M–$50M; Series B $14M–$250M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Sofía — Improving the way millions of people take care of their health
- Transak — Transak offers a simple integration to allow your users to buy more than 100+ cryptocurrencies with credit/debit cards, or bank transfers in more than 120+ countries.
- Yuetong Eye Clinic — Yuetong Eye Clinic is a medical institution that provides myopia surgery for adults and myopia prevention and control for adolescents. It is a medical institution focusing on adult myopia surgery and adolescent myopia prevention and control.
Longpan Investment is an investment firm.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Cayman Islands
Investor stats
- Total investments: 40
- Round size: Seed $14M–$60M; Series A $14M–$30M; Series B $14M–$37M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- Bodie Hekang — Bodie Hekang is a biopharmaceutical services company dedicated to advancing therapies for autoimmune and inflammatory diseases. Combining translational research, preclinical development, and clinical support, the company specializes in engineering and developing regulatory T cell (Treg) immunotherapies designed to restore immune tolerance andreduce pathological inflammation. Bodie Hekang partners with academic institutions, biotech firms, and pharmaceutical companies to provide end-to-end services that include target validation, cell manufacturing process development, potency and safety testing, and regulatory strategy support. Its multidisciplinary team of immunologists, cell biologists, and clinical development experts focuses on innovative approaches to enhance Treg stability, specificity, and functionality, aiming to translate promising laboratory findings into scalable, clinically viable treatments for conditions such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus.
- Qinghui Liannuo — Qinghui Liannuo is a scientific and technological innovation enterprise that transforms Tsinghua University's achievements in the research and development and application of immunotherapy technology. Actively promote the development of the γδ-T cell immunotherapy industry. Committed to bringing good news to patients with refractory andrecurrent solid tumors and hematomas.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 195
- Round size: Series A $1.7M–$55M; Series B $10M–$100M; Series C $14M–$200M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- ChipSine — ChipSine is an Integrated Circuit (IC) design company that focuses on the research and development of automotive-grade electronic control chips.
- Empower — Empower is an enterprise platform focused on intelligent laser manufacturing that makes lasers smart.
- Neowise — XinjingZhiyuan is an immune cell therapy company focusing on solid tumors.
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Health Care
- Stage:Series A, Series B, Angel
- Geography: China, United States, Canada
Investor stats
- Total investments: 191
- Round size: Angel $425k–$2.9M; Series A $1.4M–$92M; Series B $9.9M–$150M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $138M in 2019
Portfolio highlights
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Sungen Biomedical — Sungen Biomedical is engaged in the development of first-in-class (FIC) antibody therapeutics.
- Signet Therapeutics — Signet Therapeutics is a cutting-edge firm that conducts research and development on cancer-targeted drugs using AI and organoid disease models.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Panlin Capital, following the investment theme of ‘consumption upgrade driven by technology innovation’, targets the start-ups which are specialized in biotechnology and data intelligence sectors.As a venture capital corporation, Panlin Capital has became professional as well as influential in the biotechnology and data intelligence sectors.Identify the entrepreneurs among scientists.Enable the innovators among entrepreneurs。
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 82
- Round size: Seed $1.4k–$28M; Series A $297k–$35M; Series B $7.1M–$57M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Lingdong Core Optics — Lingdong Core Optics is a high-tech firm that specializes in the design and implementation of silicon-based integrated optoelectronic chips.
- UniXell Biotechnology — Yuesai Biotechnology is a new-generation cell therapy drug developer, focusing on the development of a new generation of cell therapy drugs.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States
Investor stats
- Total investments: 63
- Round size: Series A $10M–$120M; Series B $11M–$110M; Series C $7M–$1.4B
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- QL Biopharma — QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases.
- Vivatides Therapeutics — Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.
- Angitia Biopharmaceuticals — Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases.
Oriza Seed Venture Capital, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. Oriza Seed is a market-oriented investment platform. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of Healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcarefield. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies, including Ascentage Pharma, Innovent Biologics, and SceneRay Corporation.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Medical
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 146
- Round size: Seed $213k–$25M; Angel $425k–$14M; Series A $1.4M–$60M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Huihe Healthcare — Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China.
- Stairway Medical — Stairway Medical is a developer of implantable brain-computer interface technology.
- Xiaolong Technology —
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, Singapore
Investor stats
- Total investments: 323
- Round size: Seed $1.4k–$14M; Series A $1.4M–$28M; Series B $11M–$43M
- Lead/follow: 51% lead, 49% follow
Portfolio highlights
- Beta Infinite — Beta Infinite approaches data and model technologies in a distinctive and distinctive way.
- Letuo Technology — Letuo Technology is a ASIC chip design & manufacturing firm focused on architecture and back end design, RTL coding, DFT, and synthesis.
- Sichuan Ingia Biosynthetic — Looking for the best stevia manufacturers and wholesale suppliers? Look no further! Ingia Bio is the top natural sweetener manufacturer with a focus on precision fermentation. Find out why we're the best in the business!
Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Internet
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 449
- Round size: Series A $1.4M–$43M; Series B $8.2M–$57M; Series C $20M–$100M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- CertiK — CertiK, the largest Web3 security service provider, uses AI and formal verification to protect and monitor smart contracts and protocols, securing the Web3 ecosystem.
- Z.ai — Z.ai develops artificial intelligence models and services built upon large-scale pretrained architectures. The company offers ChatGLM, a dialogue-focused language model series designed for smooth conversation and easy integration. It also provides Ying, a text-to-video model capable of generating short video clips from text or images, and AutoGLM,a voice-driven AI agent that performs smartphone tasks based on complex user instructions. Z.ai supports integration through an API platform and offers migration assistance for developers moving from other AI ecosystems. The company’s technology stems from research at Tsinghua University’s KEG lab and emphasizes general-purpose cognitive intelligence models.
- Darma — DARMA - Digital Healt
Taiyu Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 34
- Round size: Seed $4.1M–$14M; Series A $13M–$37M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Immunocan — Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs.
- Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
- Infineon Multiomics — Infineon Multiomics is a biotechnology company that provides research and application of space multiomics technology.
Gaorong Capital is a venture capital firm that focuses on early and growth stage investments in TMT, including AI and frontier technologies.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 280
- Round size: Seed $2.8M–$57M; Series A $2.8M–$71M; Series B $14M–$120M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2020
Portfolio highlights
- GravityXR — GravityXR is an XR chip developer and a terminal equipment manufacturer serving the XR (AR/VR/MR) field, providing chip platforms for virtual reality, augmented reality and mixed reality as well as supporting hardware solutions, including platforms A complete set of technical services including software and technology suites includingapplication interfaces, key component selection, product prototype development support, etc.
- PDD Holdings — Pinduoduo is an e-commerce platform allowing users to participate in group buying deals, mostly through Tencent’s Wechat app. The company was founded in 2015 and is based in Shanghai, China.
- XYZ Robotics — XYZ Robotics develops AI-enabled robotic perception and manipulation technology for logistics and manufacturing automation. The company develops autonomous robotic solutions for put wall sorting and goods-to-person picking. Its robot sorts unorganized, random warehouse goods into groups of customer orders. The solution embodies its strength in deeplearning and robotics.
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Angel
- Geography: China, United States, Germany
Investor stats
- Total investments: 136
- Round size: Angel $425k–$15M; Series A $1.4M–$63M; Series B $3.5M–$147M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- SenseTime — SenseTime Medical is an AI healthcare firm that creates solutions for hospitals, research institutions, and the global medical market. Through its SenseCare platform, the company provides over 40 specialized AI modules and maintains strategic partnerships with organizations like Roche, Midea, and Ruijin Hospital to streamline patient services andmedical innovation.
- GigaAI — Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space.
- Falcon Technology — Falcon Technology focuses on DSA processor design innovation, developing a dedicated computing technology ecosystem based on the RISC-V architecture to deliver high-performance, energy-efficient processing solutions for next-generation intelligent computing applications.
Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 77
- Round size: Series A $1.4M–$76M; Series B $14M–$87M; Series C $14M–$74M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Yuewei Medical — Yuewei Medical is a developer of cardiac surgery interventional medical devices.
- Carbon Life — Carbon Life is a carbon sequestration technology developer. It is mainly engaged in carbon emission reduction, carbon conversion, carbon capture, carbon sequestration technology research and development.
- Westlake Therapeutics — Q1 2022 c-suite not found.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Lotus Lake Ventures is an investment firm committed to investing in science and technology innovation enterprises, focusing on high-tech and high-tech enterprises with core competitiveness in the initial stage and growth stage..
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, India
Investor stats
- Total investments: 77
- Round size: Seed $42k–$72M; Series A $709k–$97M; Series B $2M–$40M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Zhitong Technology — Zhitong Medical is a provider of computational imaging technology that focuses on the development of surgical vision.
- Fulinlan Technology — Fulinlan is committed to the planning, design, development, structural analysis, equipment processing and installation of non-standard proprietary equipment, precision parts and other products in the field of aerospace.
- Huanying Medical — Huanying Medical specializes in ultrasound technology and independently develops its core components.
Sinopharm Capital is a private equity arm of China National Pharmaceutical Group Corporation that specializes in medical and healthcare, pharmaceuticals, biotechnology, medical devices, healthcare and medical supply, and services for elderly and persons with disability. It seeks to invest in China. Sinopharm Capital was founded in June 2012 and isbased in Shanghai, China.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Canada
Investor stats
- Total investments: 49
- Round size: Seed $1.4M–$14M; Series A $1.4M–$28M; Series B $9.2M–$114M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — raised $150M in 2019
Portfolio highlights
- Metanovas Biotech — Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning.
- Artivila Therapeutics — Artivila Therapeutics is a pharmaceutical company focused on improving patient's lives through an AI-powered drug discovery engine. The company is committed to discover the best therapeutical solutions to neuro-degenerative diseases, cancers, and autoimmune diseases empowered with an integrated AI-driven innovative drug discovery platform,providing first-in-class new molecules consistently and efficiently.Artivila Therapeutics was founded in 2018 and is based in ShenZhen, China.
- Jinju Biopharmaceuticals — Jinju Biotechnology is a high-tech enterprise specializing in the research and development of stem cell therapies.
Volcanics Venture was founded in May 2016. They identify, invest in, and serve the most promising companies and outstanding entrepreneurs in Internet Innovation, Intelligent Technology and Healthcare industry. Managing Partners Suyang Zhang, Yeshun Dong and Ying Wu have been working closely for years as first-class USD/RMB fund managers.They have more than 60 years of aggregated VC investment and corporate management experience, as well as in-depth understanding of three focused fields. Volcanics Venture brings a powerful combination of global perspective and local experience to investment management, striving to provide sustainable value-added service to their portfolio companies and bring superior return to their limited partners.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 102
- Round size: Seed $350k–$17M; Series A $425k–$21M; Series B $5.7M–$60M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $73M in 2018
Portfolio highlights
- Huleen — Huleen is committed to opening up application boundaries and bringing together more information.
- Unisic — Unisic designs and manufactures silicon carbide core power components. Unisic develops sets of products based on silicon carbide and has applied silicon carbide power modules to aviation, new energy power generation, high-end medical care, oil exploration, lighting, new energy vehicles, data centers, and other important fields.
- EVAS Intelligence — EVAS Intelligence is an autonomous driving chip startup. The company was founded by Liu Hui.
Tiantu Capital is a venture capital association.
Show more...Investment focus
- Industry: Food and Beverage, E-Commerce, Health Care
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 130
- Round size: Series A $1.4M–$16M; Series B $14M–$142M; Series C $14M–$162M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — raised $68M in 2019
Portfolio highlights
- LAN —
- Zdeer — Zdeer is a health tech brand focusing on artificial intelligence health and consumer medicine. It is committed to improving the health awareness of the whole people, while breaking the shackles of the traditional health industry, through continuous technological innovation and product innovation, to bring better-looking and better-use products toconsumers at a more affordable price.
- Billy Information — Mycooltv leverage advanced AI technology to create cost-effective solutions for premium hotel experiences. AI travel media network.
ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, E-Commerce
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 374
- Round size: Seed $650k–$20M; Angel $425k–$21M; Series A $1.4M–$28M
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — raised $130M in 2022
Portfolio highlights
- Ehang — Ehang is a technology enterprise focused on R&D and production in airplane and aircraft field. With the combination of software and hardware techniques, it self-developed the communication and real-time viewing hardware and a smartphone operation system. Its product, Ghost, is accepted as the first truly smartphone app operated intelligentrobot, which is widely used in geographical information surveying, professional television aerial filming, roadshow displaying, disaster rescuing and delivery, surveillance and monitoring, and even expected to play important role in the future logistics areas.Ehang was founded in 2014 by makers from China, America, and Singapore who are enthusiastic about drone flying. The enterprise’s core members graduated from Tsinghua University, Peking University, and Duke University in America.
- ImageDT — ImageDT is a Enterprise services company.
- Snowplus — SNOWPLUS is an e-cigarette brand that provides users with e-cigarette products through a combination of online and offline sales models. The products are available in 12 different types of flavors. The products use TrueFeel honeycomb ceramic atomization technology and Aeroflow intake. Technology; In addition to reference to the existing food-gradestandards in China, Xuejia has also passed a number of third-party certifications in terms of safety. The core components such as atomizing core and cigarette holder comply with the highest medical safety standards of the FDA and the European Union.
Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 251
- Round size: Seed $2.9M–$74M; Series A $1.4M–$50M; Series B $2.9M–$100M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Xellar Biosystems — Xellar Biosystems is a wet artificial intelligence biotechnology company that provides analysis of drug testing and treatment.
- Qingyu Technology — Qingyu Technology is a software development service company specializing in the research, development, and sales of intelligent robots.
- Lightwheel — Light Wheel Intelligence is offers automated, physically precise and controllable, real and generalizable synthetic data solutions to build AI data infrastructure,
Plum Ventures is a venture capital company that aims to encourage young people to become entrepreneurs. It specializes ins providing seed and early-stage investments in the technology, new media, and telecommunications industry. The firm was founded in May 2014 and is based in Changzhou, China.
Show more...Investment focus
- Industry: E-Commerce, Manufacturing, Software
- Stage:Series A, Angel, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 209
- Round size: Seed $1.4M–$10M; Angel $425k–$6M; Series A $1.4M–$16M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Huimaiche — Huimaiche is a company that provides full-chain solutions for new retail in the automotive industry. It is an Internet-based high-tech company that combines online system development, brand management, full-brand automobile sales, aftermarket integration, and new retail in life.
- Shala Shike — Shala Shike is a supply chain technology company that focuses on catering, dining, salad carving service, cold chain distribution, and smart machine unmanned sales services.
- Titanium Robotics Technology — Titanium Robotics Technology specializing in the development and production of advanced robot hardware and solutions. It focuses on customized services, R&D, and production of robot hardware, aiming to create high-performance, industry standard products, develops lightweight, collaborative robots, humanoid robots, and exoskeletons, leading thesupply chain towards lightweight, miniaturization, and ease of use.
Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series A, Series C
- Geography: China, United States, Singapore
Investor stats
- Total investments: 331
- Round size: Series A $2.9M–$142M; Series B $14M–$219M; Series C $15M–$220M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — raised $11B in 2018
Portfolio highlights
- Sainte — Sainte is a company which provides professional nutritional solutions for babies with different nutritional needs
- Vita Dynamics — Vita Dynamics involves learning through real-world interactions by developing robots that can physically engage with their environment, they can adapt more naturally and efficiently.
- NeueHCT — Horizon Continental Technology is a joint venture between Continental Group and Horizon Robotics
Sinovation Ventures is a full-service venture capital firm that actively invests in the Chinese technology market.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Internet
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 261
- Round size: Seed $1M–$10M; Series A $1.4M–$28M; Series B $10M–$110M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $203M in 2022
Portfolio highlights
- ImageDT — ImageDT is a Enterprise services company.
- Sand.ai — Sand AI is an AI company that focuses on producing videos.
- Ruoban Technology — Ruoban Technology, an embodied intelligence firm, is focused on the study and development of intelligent robots for unstructured household scenarios.
CASH invests in emerging industries such as information technology and healthcare and focuses on fast-growing businesses in the start-up and growth stage.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States
Investor stats
- Total investments: 83
- Round size: Series A $1.4M–$30M; Series B $14M–$43M; Series C $30M–$113M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- BOTSINGTECH — BOTSINGTECH is an enterprise specialized in R&D and manufacturing of trackless guided all position crawling welding robot systems.
- Lizheng Technology — Lizheng Technology offers a selection of low-altitude security solutions, drone detection and services through technological advancement and product development.
- SuperMagnetic New Energy — SuperMagnetic New Energy is a cutting-edge innovation center and engineering incubator.
Health Care Investor funding in China at a glance
Stats across 5.5k deals from 4.6k investors.
Access all 4611 investors in China Health Care startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Health Care Investors in China investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 4611 investors investing in China Health Care startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!